Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Satellos Bioscience Inc Com V.ICO


Primary Symbol: ICOTF

iCo Therapeutics Inc is a Canada based biotechnology company. It is involved in the Research and development of ophthalmic indications. The company identifies, develops, and commercialize drug candidates with clinical history, and re-doses, reformulates and develops these drug candidates to treat sight and life-threatening diseases. Its in-licensed assets are iCo-008 and the Oral AmpB Delivery System. iCo-008 is a human monoclonal antibody targeting eotaxin-1 that acts as a messenger between...


GREY:ICOTF - Post by User

Post by Hampoooon Jun 12, 2018 1:07am
37 Views
Post# 28158034

Candidiasis Market is Expected to Grow at High CAGR

Candidiasis Market is Expected to Grow at High CAGR Candidiasis Market is Expected to Grow at High CAGR During the 2018 June 11, 2018 - by Analytical Research Cognizance Latest Report: Trends and Top Manufacturers analysis of Candidiasis Market Forecast to 2025 The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type. Pipeline Products covered across the following Developmental Stages: Clinical Non-clinical Inactive: Discontinued and/or Dormant Descriptive coverage of pipeline development activities for Candidiasis Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Browse Full Report@: https://www.arcognizance.com/report/candidiasis-pipeline-insight-2018 Pipeline Therapeutics assessment of products for Candidiasis The report assesses the active Candidiasis pipeline products by developmental stage, product type, molecule type, and administration route. Methodology Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsights team of industry experts. Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases. Scope of the report The report provides a snapshot of the pipeline development for the Candidiasis The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Candidiasis The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Candidiasis The report also covers the dormant and discontinued pipeline projects related to the Candidiasis Reasons to Buy Establish comprehensive understanding of the pipeline activity across this Candidiasis to formulate effective R&D strategies Gather information of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine Plot corrective measures for pipeline projects by understanding the pipeline depth and focus of Candidiasis therapeutics Devise in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Modify the therapeutic portfolio by identifying inactive projects and understanding the factors that might have halted their progress Company Mentioned: Amplyx Pharmaceuticals Inc Bakker Medical Srl Biomar Microbial Technologies Biosergen AS Cidara Therapeutics Inc CSA Biotechnologies LLC Daewoong Pharmaceutical Co Ltd Dermala Inc General Biologicals Corp Grupo Ferrer Internacional SA Hsiri Therapeutics LLC iCo Therapeutics Inc. ImmunoClin Corp & list continues
<< Previous
Bullboard Posts
Next >>